

Application No.  
Amendment Dated  
Page 2 of 7


10/560,C38  
08/23/2006

### Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application.

### Claims:


1. (Currently Amended) A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,



wherein -N-HET is



Q is







R<sub>2</sub> and R<sub>3</sub> are independently selected from H, F, Cl, CF<sub>3</sub>, OMe, SMe, Me and Et;

T is selected from the groups in (TAa1) to (TAa12):

Application No.  
Amendment Dated  
Page 3 of 7

10/550,038  
08/23/2006



wherein :

$R^{6h}$  is hydrogen or (1-4C)alkyl;

$R^{4h}$  and  $R^{5h}$  are independently selected from hydrogen, cyano, hydroxy(1-4C)alkyl, cyano(1-4C)alkyl, phosphoryl(1-4C)alkyl, benzyl (optionally substituted on the phenyl ring by one substituent selected from halo, methyl and methoxy), (1-4C)alkyl, (1-4C)alkyl substituted with ORc (wherein Rc is  $R^{13}CO$  and  $R^{13}$  is selected from Rc2b), (1-4C)alkanoyl and (1-4C)alkoxycarbonyl;

(Rc2b) (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, carboxy, phosphoryl [-O-P(O)(OH)<sub>2</sub>], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinyl [-O-P(OH)<sub>2</sub> and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from phosphonate [phosphono, -P(O)(OH)<sub>2</sub>], and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, phosphinate [-P(OH)<sub>2</sub> and mono- and di-(1-4C)alkoxy derivatives thereof], trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)<sub>p</sub>NH-, (1-4C)alkylS(O)<sub>p</sub>((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)<sub>p</sub>NH-, fluoro(1-4C)alkylS(O)<sub>p</sub>((1-4C)alkyl)N-, (1-4C)alkylS(O)<sub>q</sub>- [the (1-4C)alkyl group of (1-4C)alkylS(O)<sub>q</sub>- being optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)(OH)<sub>2</sub>], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinyl [-O-P(OH)<sub>2</sub> and mono- and di-(1-4C)alkoxy derivatives thereof], amino, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, carboxy, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-

Application No.  
Amendment Dated  
Page 4 of 7

10/550,038  
08/23/2006

6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)<sub>p</sub>NH-, (1-4C)alkylS(O)<sub>p</sub>-((1-4C)alkyl)N-, and (1-4C)alkylS(O)<sub>q</sub>-.


2. (Cancelled)

3. (Cancelled)

4. (Previously Presented) The compound of claim 1, wherein R<sup>2</sup> and R<sup>3</sup> are independently hydrogen or fluoro.

5. (Cancelled)

6. (Previously Presented) The compound of claim 1, which is a compound of formula (IB)



wherein

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen or fluoro;

R<sup>6h</sup> is hydrogen or (1-4C)alkyl;

R<sup>4h</sup> and R<sup>5h</sup> are independently selected from hydrogen, cyano, hydroxy(1-4C)alkyl, cyano(1-4C)alkyl, phosphoryl(1-4C)alkyl, benzyl (optionally substituted on the phenyl ring by one substituent selected from halo, methyl and methoxy), (1-4C)alkyl, (1-4C)alkyl substituted with OR<sub>c</sub> (wherein R<sub>c</sub> is R<sup>13</sup>CO and R<sup>13</sup> is selected from R<sub>c2b</sub>), (1-4C)alkanoyl and (1-4C)alkoxycarbonyl.

7. (Cancelled)

8. (Previously Presented) A method for producing an antibacterial effect in a warm blooded animal which comprises administering to said animal an effective amount of a compound of claim 1.

9 – 10. (Cancelled)

Application No.  
Amendment Dated  
Page 5 of 7

10/550,038  
08/23/2006

11. (Previously Presented) A pharmaceutical composition which comprises a compound of claim 1, and a pharmaceutically-acceptable diluent or carrier.

12. (Canceled)

13. (Previously Presented) A compound which is

(5*R*)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

Ethyl 5-{2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}isoxazole-3-carboxylate;

(5*R*)-3-[3-Fluoro-4-[3-(hydroxymethyl)isoxazol-5-yl]phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}isoxazol-3-yl)methyl dihydrogen phosphate;

1-Methyl-3-{4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1*H*-pyrazole-5-carbonitrile;

1-Methyl-3-{4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1*H*-pyrazole-5-carbaldehyde;

(5*R*)-3-[3-Fluoro-4-(1*H*-1,2,3-triazol-4-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5*R*)-3-[3-Fluoro-4-(1-methyl-1*H*-1,2,3-triazol-4-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5*R*)-3-[3-Fluoro-4-(2-methyl-2*H*-1,2,3-triazol-4-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(4-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1*H*-1,2,3-triazol-1-yl)acetonitrile; or

(4-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-2*H*-1,2,3-triazol-2-yl)acetonitrile.